I receive lots of company news snippets. This came my way this morning. Sounds positive news for health, share price dip not so good news for investors. Worth watching the drug developments. Lets all hope its positive.

GlaxoSmithKline slipped a little even as it and Innoviva reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.GlaxoSmithKline slipped a little even as it and Innoviva reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.